BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Aug 08, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Taliglucerase alfa regulatory update

Protalix submitted a reply to a February complete response letter from FDA for Gaucher's disease candidate taliglucerase alfa. The company expects to receive a new PDUFA date within weeks. The response includes additional data from a switchover trial and...

Read the full 174 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >